Group items tagged

Prevalence of vitamin d insufficiency in patients with Parkinson disease and Alzheimer disease.\nEvatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V.\nArch Neurol. 2008 Oct;65(10):1348-52.\nPMID: 18852350

Vitamin D is a fat-soluble vitamin that is essential for maintaining normal calcium metabolism (1). Vitamin D3 (cholecalciferol) can be synthesized by humans in the skin upon exposure to ultraviolet-B (UVB) radiation from sunlight, or it can be obtained from the diet. Plants synthesize ergosterol, which is converted to vitamin D2 (ergocalciferol) by ultraviolet light. Vitamin D2 is less active in birds than vitamin D3 and may also be less active in humans (2). When exposure to UVB radiation is insufficient for the synthesis of adequate amounts of vitamin D3 in the skin, adequate intake of vitamin D from the diet is essential for health.

"This website is about Vitamin D and MS Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), with an uncertain cause. Colleen Hayes and Donald Achaeson have suggested that insufficient sunlight exposure and chronic viral infections might be unrelated environmental risk factors for MS. These risk factors may act synergistically to enable the pathogenic autoimmune response. The prevalence of MS is highest where environmental supplies of vitamin D are lowest. Sunshine enables the production of vitamin D3 (VD3) in the skin. Epidemiological studies have shown that higher vitamin D blood levels are associated with lower risk, less relapses and a slower progression of multiple sclerosis. Higher vitamin D levels can be achieved in part by increased oral intake of VD3. Optimal health requires serum 25 hydroxyvitamin D levels higher than 20 ng/ml (50 nmol/L) P Lips, 40 ng/ml (100 nmol/L) P Heaney or at least 40 ng/ml (100 nmol/L) R Vieth. "

Vitamin D in preventive medicine: are we ignoring the evidence? Zittermann A. Br J Nutr. 2003 May;89(5):552-72. Review. PMID: 12720576

Primary vitamin D deficiency in adults.\nDrug Ther Bull. 2006 Apr;44(4):25-9. Review.\nPMID: 16617932 [PubMed - indexed for MEDLINE]

Chatfield SM, Brand C, Ebeling PR, Russell DM. Vitamin D deficiency in general medical inpatients in summer and winter. Intern Med J. 2007 Jun;37(6):377-82. PMID: 17535381 [PubMed - in process]

van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Taylor BV, Kilpatrick T, Butzkueven H, McMichael AJ. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007 May;254(5):581-90. Epub 2007 Apr 11.

Zittermann A, Schleithoff SS, Koerfer R. \nVitamin D and vascular calcification.\nCurr Opin Lipidol. 2007 Feb;18(1):41-6. Review.\nPMID: 17218831 [PubMed - indexed for MEDLINE

Not enough vitamin D: health consequences for Canadians. Schwalfenberg G. Can Fam Physician. 2007 May;53(5):841-54. Review PMID: 17872747 Conclusion Low levels of VTD are considered a major public health problem in Canada, especially during the winter. Those with risk factors should be screened for low 25(OH)D levels and repletion therapy instituted if needed. Researchers have estimated that the oral dose of vitamin D3 to attain and maintain 25(OH)D levels >80 nmol/L is 2200 IU/d if baseline levels are 20 to 40 nmol/L, 1800 IU/d if levels are 40 to 60 nmol/L, and 1160 IU/d if levels are between 60 and 80 nmol/L.64 We need to ensure that patients have healthy blood levels of 25(OH)D to prevent levels of parathyroid hormone from rising and to maximize absorption of calcium, magnesium, and phosphate. Positive effects on bone are marginal at best unless patients consume at least 800 IU/d of VTD. The emerging and exciting role of the VTD receptor and the actions of VTD in maintaining health in other cell types have become more apparent during the last decade.